ATTORNEY'S DOCKET NUMBER

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371

IVD 913

U. S. APPLICATION NO. (If known, see 37 CFR 1.5)

09/125005

INTERNATIONAL APPLICATION NO. PCT/FR97/00214

INTERNATIONAL FILING DATE February 3, 1997

PRIORITY DATE CLAIMED February 2, 1996

TITLE OF INVENTION **PURIFIED SR-p70 PROTEIN** APPLICANT(S) FOR DO/EO/US CAPUT, Daniel, FERRARA, Pascual and KAGHAD, Ahmed Mourad Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: 1. This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 2. This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay 3. examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1)). 4. A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. 5. A copy of the International Application as filed (35 U.S.C. 371(c)(2)) a. \square is transmitted herewith (required only if not transmitted by the International Bureau). , **J** b.

has been transmitted by the International Bureau. c. \square is not required, as the application was filed in the United States Receiving Office (RO/US). ľIJ [f 6. ⊠ A translation of the International Application into English (35 U.S.C. 371 (c)(2)). IJ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3)) a. \square are transmitted herewith (required only if not transmitted by the International Bureau). ΙĦ b. \square have been transmitted by the International Bureau. c. have not been made; however, the time limit for making such amendments has NOT expired. 13 d. \(\square\) have not been made and will not be made. 8. A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)). 9 🛛 An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11. to 16. below concern document(s) or information included: An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. 🖂 An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. A FIRST preliminary amendment. A SECOND or SUBSEQUENT preliminary amendment. 14. □ A substitute specification. A change of power of attorney and/or address letter. 15. 16. Other items or information:

U.S. AFFEIGATION NO. (II KI	ATERNA	PCT/FR97/002	214	ATTORNEY'S DOCKET NUM IVD 913		
17. The following fees are submitted:				CALCULATIONS PTO USE ONLY		
BASIC NATIONAL FEE (37 CFR 1. 492 (a)(1)-(5)):				On Dood In the last	TO OSE CITE!	
Search Rep	ort has been prepared by the	he EPO or JPO	\$930.00			
International preliminary examination fee paid to USPTO (37CFR 1.482)				ĺ		
NTs ::::4::::				İ		
No internati	ional preliminary examina ional search fee paid to US	tion fee paid to USPTO) (37 CFR 1.482)	İ		
	i					
internationa	ernational preliminary examal search fee (37 CFR 1.44	5(a)(2)) paid to USPTC	\$1,070,00			
Internationa	ĺ					
and all clair	ms satisfied provisions of l	PCT Article 33(2)-(4).	\$98.00	i		
	ENTER APP	ROPRIATE BASIC	FEE AMOUNT =	\$ 930.00		
	for furnishing the oath or		[]20[]30	\$		
	iest claimed priority date (
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE			
Total claims	38-20 =	18	x \$22.00	\$ 396.00		
Independent claims	5 - 3 =	2	x \$82.00	\$ 164.00		
MULTIPLE DEPEN	DENT CLAIM(S) (if appl		+ \$270.00	\$		
TOTAL OF ABOVE CALCULATIONS =				\$1490.00		
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement				\$		
must also be filed (Note 37 CFR 1.9, 1.27, 1.28). SUBTOTAL =				\$1490.00		
Processing fee of \$130.00 for furnishing the English translation later than [] 20 [] 30				\$		
months from the earliest claimed priority date (37 CFR 1.492 (f)).				"		
TOTAL NATIONAL FEE =				\$		
Fee for recording the enclosed assignment (37 CFR 1.21(h). The assignment must be				\$ 40.00		
accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +						
TOTAL FEES ENCLOSED =				\$1530.00		
				Amount to be	\$ ·	
•				refunded:	#1.530 00	
				Cnarged	\$1530.00	
a. A check in the amount of \$ to cover the above fees is enclosed.						
to cover the above fees is enclosed.						
b. Please charge my Deposit Account No. 19-0091 in the amount of \$1530.00 to cover the above fees. A duplicate copy of this sheet is enclosed.						
c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0091. A duplicate copy of this sheet is enclosed.						
		-				
	appropriate time limit un · (b)) must be filed and gr				ive (37 CFR	
SEND ALL CORRESPONDENCE TO: SIGNATURE DATE The state of the state o					7/29/98	
Mary P. Bauman			310147	Mary P. Bauman	DATE	
Patent Department NAME				3		
Sanofi Pharmaceuticals, Inc.				31,926		
9 Great Valley Parkway REGIS P.O. Box 3026				TRATION NUMBER		
Malvern, PA 19355						
Malvern, PA 19355		4		(610) 889-6338		
Malvern, PA 19355		,	TELEP	(610) 889-6338 PHONE NUMBER		



12 Rec'd PCT/PTO*30 170113998

Application of: CAPUT, Daniel, FERRARA, Pascual and KAGHAD, Ahmed Mourad

Docket No.: IVD 913

Filing Under U.S.C. §371

Filed as a U.S. National Phase Application of
International Application Serial No. PCT/FR97/00214

Filed: February 3, 1997

FOR: PURIFIED SR-p70 PROTEIN

CERTIFICATE UNDER 37 CFR 1.10

Express Mail Mailing Label Number <u>EM317281100US</u>
Date of Deposit
I hereby certify that this paper is being deposited with the United States Postal Service
"Express Mail Post Office To Addressee" Service on the date indicated above and is
addressed to: Assistant Commissioner For Patents, Box PCT, Attn: EO/US,
Washington, D.C. 20231
Joan M. Alglerike
Signature